At LVMH, Chairman and CEO of Louis Vuitton, Jordi Constans announced he was stepping down due to the discovery of a significant health issue, to which Michael Burke has now filled the position.
Burke, a dual French-U.S. citizen, joined the Group in 1986 and following the acquisition of Fendi by LVMH in 2003, was appointed CEO, transforming the brand into the success that it is today.
Although sad to see Constans go, Bernard Arnault, Chairman and CEO of LVMH has faith that Burke will keep his initatives going, “I am convinced that he is the right leader for Louis Vuitton’s future; he will build on the initiatives launched by Jordi Constans, bringing the vision and drive to continue advancing Louis Vuitton’s leadership position in luxury.”
Bayer MaterialScience appoints James Charron
Elsewhere, Bayer MaterialScience announced it had appointed James Charron as head of its' application development, for its Coatings, Adhesives and Specialties (CAS) business unit.
Charron joined Bayer in 2000 as a polyether polyol process development scientist and has held several positions in business development.
With this new role, he is set to lead development activities across CAS technologies in the North America region, and co-ordinate regional and global application development projects.
Seven Scent expands its perfumery team
Meanwhile, Seven Scent has recruited Peter Malton to its creative perfumery team where he will be responsible for creating new fragrances, both for its expanding external customer base and PZ Cussons brands.
Malton joins Seven following 20 years with P&G where he was involved with many categories in the company’s beauty care portfolio including Olay, Wella and Hugo Boss.
“Peter brings extensive experience to his new role at Seven; combining R&D and new technology with creative perfumery and FMCG expertise. We are delighted to welcome him to the team,” says Seven’s head of marketing and innovation, Bruce Furlonger.
And finally Genemarkers, a genomics service provider, announced this week that Dr. Nava Dayan has joined it’s scientific team to promote business development in skin care.
The company is said to be the first to offer the personal care industry a gene expression panel to assist scientists on the effects of UV exposed skin.
"Dr. Dayan's expertise in skin biology will complement our strength in genomics. Together we will be able to provide more comprehensive and valuable services to our customers and we are excited to have her join our team,” said CEO Dr. Anna Langerveld on the appointment.